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• Medical termination of pregnancy with mifepristone, a 
progesterone antagonist, is available to women in North 
America, the United Kingdom, much of Western Europe, 
Russia, China, Israel, New Zealand, Turkey and Tunisia, 
but not Australia.
• Experience of mifepristone use in around two million 
abortions has shown that it is safe, effective, cheap to 
produce, and highly acceptable to women.
• Mifepristone is usually used in combination with a 
prostaglandin analogue, such as misoprostol; these drugs 
have been added to the World Health Organization’s list of 
essential medicines for developing countries.
• Availability of this drug in Australia might largely overcome 
many of the inequities of access to abortion, and is critical for 
many women in rural areas and women in some ethnic groups 
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whose access to surgical abortion is limited.ece
do
reqR ntly, a young woman from a rural community presented to actor in a small country hospital some distance from her home,uesting termination of pregnancy. She was the mother of two
children aged under 3 years, both delivered before 32 weeks gestation
because of severe pre-eclampsia. Her partner was unsupportive. At
presentation, she was 8 weeks pregnant.
The doctor was sympathetic to her request but was unable to arrange
surgical termination in the country hospital. He advised that she would
need to travel, by bus and at her own expense, several hundred
rtion could be
an $700 in all.
d she returned
untry hospital,
r to the town in
ed, where she
underwent emergency caesarean section in a public hospital. The infant
died within 24 hours, and the woman spent several days in a high-
dependency unit. The cost of her transfer and hospitalisation was
covered from the public purse.
This woman’s story could have been very different if Australian
women, like those in the United States, Canada, the United
Kingdom, much of Western Europe, Russia, China, Israel, New
Zealand, and more recently countries such as Turkey and Tunisia,
had access to medical abortion. This woman’s story could have
been very different if Australian women had access to mifepristone
(formerly known as RU-486), a drug which is safe, effective, cheap
to produce, and now widely used overseas for medical abortion.
More than 1.5 million early (before 9 weeks) terminations of
pregnancy have been performed in Europe, and around 400 000 in
the US, using mifepristone together with prostaglandin analogues.
There is a large body of literature now available on the administra-
tion, effectiveness, side effects and risks of the medication, as well
as much information about its acceptability to women.1-11
Mifepristone and termination of pregnancy
Mifepristone is a synthetic steroid that blocks the actions of
progesterone. It was developed in France in 1980 and underwent
clinical trials in France and Switzerland in 1981.1-3,12 It was licensed
for use in France in 1988, the UK in 1991, and the US in 2000.
The drug can be used for emergency contraception as an
alternative to levonorgestrel, as well as to induce menstruation
before a period has been missed; it can also be used to bring about
abortion, either in early pregnancy or in the second trimester.2,4,12
It acts by inhibiting the action of progesterone in the maintenance
of early pregnancy, causing degeneration of the decidua, and thus
the separation of the developing embryo and placenta from the
uterine wall; it also causes cervical softening and the release of
endogenous prostaglandins. When used for medical termination of
pregnancy, mifepristone is usually administered with a prostaglan-
din analogue (either misoprostol or gemeprost), which brings
about expulsion of the uterine contents.
In early pregnancy, various drug regimens have been used, most
commonly mifepristone (200 mg orally) followed by the prostag-
landin analogue misoprostol (one or more doses vaginally or
orally), either commencing at the time mifepristone is given or 1–
3 days later. Misoprostol may be given by a clinician or adminis-
tered by the woman herself.1-3,5-7 (Misoprostol is currently avail-
able in Australia and, although not listed for gynaecological
indications, it is used for cervical dilatation before surgical uterine
evacuation and for postpartum haemorrhage; it has also been used
overseas to treat incomplete spontaneous abortion.)
In 93%–98% of cases, administration of the drug combination
leads to complete abortion. In the remainder, the abortion needs to
be completed by aspiration of uterine contents by an appropriately
qualified doctor. In a very small number of women, heavy vaginal
bleeding necessitates hospital admission and sometimes transfu-
sion (transfusion rates of 1 per 1000 and 2.5 per 1000 are cited in
various studies). Infection of retained products of conception is a
possibility, and antibiotics may be needed.1-3,5-8
Mifepristone is also very effective for second trimester termina-
tion, again in conjunction with misoprostol or another prostaglan-
din analogue.
The context of use
All women requesting termination of pregnancy require complete
and accurate information about procedures, and counselling rele-
vant to their particular medical, psychological and social situation
— this is true of medical as well as surgical abortion.ber 7 • 3 October 2005
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ine is essential, and any suggestion of ectopic pregnancy necessi-
tates specialist referral. The drugs for medical abortion must be
prescribed by a practitioner with appropriate training; the oppor-
tunity may also be taken to carry out cervical screening and
screening for sexually transmitted infections. Mifepristone should
be administered within a medical context, but misoprostol may be
given for the woman to self-administer. There is no need for the
woman to remain under medical observation; the abortion process
can occur at home, but the woman must have access to appropri-
ate and skilled 24-hour emergency help if needed.1-3,7,8 Analgesia
must be offered (pain and bleeding are a normal part of the
process), and the woman should be supported emotionally as
much as possible. Follow-up to confirm that all products of
conception have been removed is essential, and the woman should
be offered contraception and further counselling if needed.
Degree of satisfaction with the method has been widely investi-
gated, with around 90% of women being “satisfied” or “very
satisfied”. In particular, the possibility for privacy and the mini-
mally invasive nature of the treatment have made it acceptable to a
large number of women.2,5-8
In second-trimester termination, overseas experience with mife-
pristone used under supervision in hospitals or clinics shows that
its use has greatly shortened and simplified the process.2,9 For
women with second-trimester diagnoses of severe fetal abnormali-
ties and those in whom major medical or psychiatric indications
for termination exist (who currently comprise most of the small
number of women undergoing late termination in Australia, as
elsewhere), the drug combination contributes hugely to ameliorat-
ing a very difficult and psychologically traumatic process.
Mifepristone in Australia
It is clear from this summary that medical abortion could be
quickly incorporated into the practice of existing Australian
abortion services, and could also easily become part of the practice
of those gynaecologists, general practitioners and family planning
doctors who wished to provide it. In particular, it could become a
real and accessible option for women in rural areas.
Most women undergoing early medical abortion do not require
any further surgical assistance or intervention, simply the easy
availability of such services if needed. Throughout rural Australia,
facilities exist in smaller hospitals for the management of women
presenting with spontaneous miscarriage; most of these cases are
managed by competent GPs, with only the occasional need for
transfer to larger hospitals. The management of incomplete medi-
cal abortion is similar, with quite modest requirements for services
and equipment. Women from more remote areas might need to
stay in the closest small town until the abortion was complete, but
would not need to travel long distances to surgical abortion clinics.
While not all rural GPs would wish to provide medical abortion, a
number would, whereas the provision of surgical abortion, with
the need for greater training, and time and financial restraints, will
never be an option for small rural centres or hospitals.
It is true that there have been some deaths associated with
medical abortions. In the US, since 2000, there has been one death
from an undiagnosed ruptured ectopic pregnancy, and another
death from myocardial infarction in a woman with known heart
disease who may have been more suited to surgical termination.3,8
While not diminishing the tragedy of any death, neither of these
was directly related to the use of mifepristone.3 Also, in the past 5
years, there have been four deaths in the US, all in California, from
post-abortion sepsis; in two cases Clostridium sordellii was the
causative organism, and in two cases investigation is ongoing.8,10
C. sordellii, a rare pathogen that produces a powerful toxin, is an
occasional commensal in the bowel or vagina. It was reported in
the American literature as a cause of death after normal or
operative vaginal delivery and gynaecological surgery before the
introduction of medical abortion to the US.13,14 It could be
postulated that the women who developed C. sordellii infection
after medical termination might equally well have developed the
infection had their pregnancies proceeded to term.8 These deaths
— four in close to 400 000 abortions in the US — must be seen in
the context of overall maternal mortality figures, currently around
12 per 100 000 births in the US.3,15 Pregnancy is never without
risk for any woman, but both surgical and medical abortion carry
less than 10% of the risk of mortality when compared with
continuing the pregnancy.15
In 1999, the International Federation of Obstetrics and Gynae-
cology (FIGO) stated that “after appropriate counselling, a woman
has the right to have access to medical or surgical induced
abortion, and . . . healthcare services have an obligation to provide
such services as safely as possible.”2 This view was supported by
the World Health Organization which, in 2003, published Safe
abortion: technical and policy guidance to assist health care providers
to make surgical and medical abortion safe and accessible.9 More
recently, WHO has added mifepristone and misoprostol to its list
of essential medicines for developing countries, medicines it
believes “satisfy the priority healthcare needs of the population”.16
Both the UK Royal College of Obstetricians and Gynaecologists
and the American College of Obstetricians and Gynecologists have
been outspoken in their support for the introduction of medical
abortion in their respective domains, seeing it as an important
health care need for women.1-3,8 In Australia to date, there have
been efforts by individual women and health care professionals,
but support for medical abortion by relevant professional bodies
has been muted.
In an article in the Journal in 2004, de Crespigny and Savulescu
examined the discrepancies in abortion laws between Australian
states, and argued the case for uniform decriminalisation of
existing laws.17 In addition, they pointed out that, although
abortion is legal in some situations in all states, there are marked
inequities of access to existing services. These inequities might be
largely overcome by the introduction of medical abortion in this
country.
The topic of abortion is an emotive and controversial one.
Recent media debate seems to have died down, and no doubt
politicians simply hope the issue will go away. It will not. We do
not know how many abortions are performed in Australia each
year, but it is believed the number is large.18 Certainly, it would be
desirable to try to reduce the figure, whatever it is, by appropriate
research and better provision of contraception. However, given the
complex and compelling nature of human sexuality, unwanted
pregnancies will continue to occur, and Australian women will
continue to seek safe, legal abortion. It is worth noting that, in
European countries where mifepristone has been available for
some time, there has been no increase in the number or rate of
abortions overall, but the proportion of abortions performed at
earlier gestations has risen. The safety of abortion has been shown
to be directly related to how early in pregnancy it is performed.15MJA • Volume 183 Number 7 • 3 October 2005 379
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on political grounds but solely on evidence-based medical criteria.
As de Crespigny and Savulescu state, there appears to be broad
community support for a woman’s right to choose an abortion after
appropriate discussion with her doctor. For many women in urban
areas, the ability to choose medical rather than surgical abortion
would simply bring their choices into line with current practice in
most of the rest of the developed world. However, for rural women
and for women of some ethnic groups for whom privacy is a
particular issue, the option of medical abortion is critical if they are
to be treated equally with other Australian women.
Recently, we have seen the rapid introduction of sildenafil and
other similar drugs into the Australian pharmacopoeia. We live in
a society where many aspects of sexual behaviour are freely
discussed and promoted. This includes the treatment of erectile
dysfunction and the recognition of the importance of this subject
to many men whose sexual lives have been enhanced by the
availability of these agents. At the same time, although unplanned
and unwanted pregnancies are a direct consequence of sexual
activity, we are as a society much less willing to acknowledge that
provision of safe, accessible abortion facilities is essential to allow
women control of their reproductive lives. It’s time to face these
facts, and to add mifepristone to the range of choices that can be
offered to Australian women.
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